TY - JOUR
T1 - Physiologic and pharmacologic determinants of vasodilator response
T2 - A conceptual framework for rational drug therapy for chronic heart failure
AU - Packer, Milton
AU - Le Jemtel, Thierry H.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1982
Y1 - 1982
N2 - This article has attempted to summarize the increasing number of pharmacologic and physiologic variables that are being recognized as important determinants in the response to vasodilator therapy in patients with severe chronic heart failure. It is apparent that a careful consideration of many factors is necessary before proper selection of a specific drug can be made for a specific patient, since not all patients with refractory heart failure demonstrate beneficial hemodynamic and clinical responses to all agents. Each patient presents us with a unique set of physiologic variables; each drug has its own advantages and limitations. Identification of those subgroups of patients most likely to benefit from a specific agent or combination of agents is a major goal for future research. Although a number of hemodynamic variables can be made to improve acutely with a wide variety of vasodilator drugs, well tolerated sustained meaningful clinical benefits are probably observed in relatively few patients. Rational and successful vasodilator therapy is possible only through a highly individualized approach.
AB - This article has attempted to summarize the increasing number of pharmacologic and physiologic variables that are being recognized as important determinants in the response to vasodilator therapy in patients with severe chronic heart failure. It is apparent that a careful consideration of many factors is necessary before proper selection of a specific drug can be made for a specific patient, since not all patients with refractory heart failure demonstrate beneficial hemodynamic and clinical responses to all agents. Each patient presents us with a unique set of physiologic variables; each drug has its own advantages and limitations. Identification of those subgroups of patients most likely to benefit from a specific agent or combination of agents is a major goal for future research. Although a number of hemodynamic variables can be made to improve acutely with a wide variety of vasodilator drugs, well tolerated sustained meaningful clinical benefits are probably observed in relatively few patients. Rational and successful vasodilator therapy is possible only through a highly individualized approach.
UR - http://www.scopus.com/inward/record.url?scp=0020008055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020008055&partnerID=8YFLogxK
U2 - 10.1016/0033-0620(82)90006-8
DO - 10.1016/0033-0620(82)90006-8
M3 - Article
C2 - 7034047
AN - SCOPUS:0020008055
SN - 0033-0620
VL - 24
SP - 275
EP - 292
JO - Progress in Cardiovascular Diseases
JF - Progress in Cardiovascular Diseases
IS - 4
ER -